It's nearly impossible to tell whether the risk evaluation and mitigation strategy (REMS) for extended-release/long-acting opioids (ER/LA) has had an impact on falling rates of abuse, overdose, and death from prescription painkillers, presenters said here.
Both company representatives and FDA officials agreed, during the first day of a 2-day advisory committee meeting, that it's difficult to discern the program's effect on these trends.
Read Full Article »